Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Shroom family member 4 (SHROOM4) is an actin-associated protein encoded by the KIAA1202 gene, primarily known for its roles in cytoskeletal organization and neural development[5][4][1]. It contains an N-terminal PDZ domain and a C-terminal ASD2 motif, which participate in intracellular protein-protein interactions, particularly affecting synaptic structure and function[3][5][2]. SHROOM4 is highly expressed in neural tissues, where it is a critical regulator of dendritic spine morphology, and modulates surface expression and trafficking of GABA_B receptors[5]. Mutations in SHROOM4 are linked to X-linked intellectual disability (Stocco dos Santos syndrome) and epilepsy, highlighting its importance in neurodevelopment and synaptic function[2][5][4]. There are no current reports of SHROOM4 being a direct therapeutic drug target and no known drug interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Shroom family member 4 (SHROOM4).